Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of BMS-986406 alone and in combination in advanced malignant tumors
jRCT2031230298Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of BMS-986406 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 11 more (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events, Number of participants with serious adverse events and 3 more. Started Sep 2023; status: completed.
02
Drugs
BMS-986406
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)pancreatic adenocarcinoma (PDAC)gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2031230298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230298.